

ASX RELEASE

ADMEDUS COMPLETES FULLY SUBSCRIBED \$16.1M RIGHTS ISSUE

- **Rights Issue oversubscribed**
- **Admedus raises a total of \$28M**

Brisbane, Australia, April 17th, 2015

Admedus Limited (ASX: AHZ) is pleased to announce that its non-renounceable Rights Issue announced on 18 March 2015 closed on 14 April 2015.

The fully subscribed Rights Issue has raised a total amount of approximately \$16.1 million (before costs and expenses of the offer). Net proceeds will be applied as described in the Offer Document lodged with the ASX on 30 March 2015. This follows on from the company's successful Placement which raised \$12.0 million.

"The company thanks shareholders for their support for this Rights Issue and the recent Placement with the total capital raised of approximately \$28 million. This will assist the progression of the Company's programs and plans as we continue to grow our integrated global healthcare business" stated Admedus CEO Mr. Lee Rodne.

Given the excess demand for Shortfall Shares from shareholders, a scale-back of requests for additional shares will be implemented so that shareholders receive a maximum of 10 times their rights entitlement.

The allotment of New Shares under the Rights Issue is scheduled to take place on 20 April 2015. Holding statements are expected to be dispatched to shareholders on 20 April 2015, which will confirm the number of shares allotted to each applicant. The New Shares are expected to commence normal trading on the ASX on 20 April 2015.

Morgans Corporate Limited acted as Lead Manager to the Rights Issue.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 3 9620 5454

Media:

Haley Price
+61 (0) 423 139 163
hprice@admedus.com

Media Europe & Asia

Consilium Strategic Communications
Jessica Hodgson / Ivar Milligan
+44 (0)20 3709 5700
admedus@consilium-comms.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com